Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published:October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like Researchers receive funding to explore factors associated with brain health in female military veterans November 8, 2023 Huntsman Cancer Institute advances interventional radiology with new angio CT suite November 12, 2025 Study analyzes lack of palliative care referrals for nursing home residents July 16, 2024
Researchers receive funding to explore factors associated with brain health in female military veterans November 8, 2023
Huntsman Cancer Institute advances interventional radiology with new angio CT suite November 12, 2025